Dana-farber-cancer Institute Inc.

Children's Medical Center Corporation

The Broad Institute, Inc.

The Board Institute, Inc.

Peter Hammerman

Matthew Meyerson

Kwok-kin Wong

Alexis Ramos

Nathanael Schiander Gray

Glenn Dranoff

Carla F Kim

Christine F Brainson

Chunxiao Xu

Chandra Pedamallu

Sam Freeman

The present invention relates to methods for identifying, assessing, preventing, and treating cancer (e.g., head, neck, and/or lung cancers in humans). A variety of PD-L1 isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with cancer status and indicates amenability to treatment or prevention by modulating PD-1 and/or PD-L1 levels.

Methods for identification, assessment, prevention, and treatment of cancer using PD-L1 isoforms

The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint inhibitor therapies.

Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response

The present disclosure provides combination therapy of a transcription inhibitor and a kinase inhibitor. The combination of the transcription inhibitor and the kinase inhibitor may be useful in treating and/or preventing in a subject a proliferative disease, such as proliferative a disease that is resistant to the transcription inhibitor alone or the kinase inhibitor alone. In certain embodiments, the proliferative disease is a cancer. The combination of the transcription inhibitor and the kinase inhibitor is expected to be synergistic.

Combination therapy of transcription inhibitors and kinase inhibitors

Methods for treating patients with squamous cell lung cancer, including detecting the presence of mutations in the discoidin domain receptor 2 (DDR2) gene.

DDR2 mutations in squamous cell lung cancer

Growing community of inventors

Newton, MA, United States of America

Peter Hammerman